American College of Rheumatology Convergence (ACR)

December 30, 2021

Catch up on Rheumatology Network's top highlights of the ACR 2021 Convergence.

December 08, 2021

Roy Fleischmann, MD, explores the successful results of the novel IL-6 inhibitor, olokizumab, from 2 randomized clinical trials of the phase 3 global research program CREDO.

December 06, 2021

On this month's episode of Overdrive, Rheumatology Network interviewed Courtney Wells, PhD, MPH, MSW, to discuss the impact of COVID-19 on the quality of life of patients with rheumatic conditions, focusing on perceived risk and decision making.

December 01, 2021

Philip Mease, MD, explains the recent Phase 3 data from the DISCOVER-1 and DISCOVER-2 clinical trials which demonstrated guselkumab inhibited radiographic progression, and improved symptoms and pain in patients with active psoriatic arthritis (PsA).

November 30, 2021

Louis Bessette, MD, MSc, explains the impact of early pain improvement on patient-reported outcomes in patients with psoriatic arthritis.

November 30, 2021

Benjamin Terrier, MD, PhD, discusses his study and ACR presentation, “Rituximab versus Conventional Therapeutic Strategy for Remission Induction in Eosinophilic Granulomatosis with Polyangiitis: A Double-blind, Randomized, Controlled Trial.”

November 29, 2021

Paul R. Fortin, MD, MPH, FRCPC, discusses the impact of the COVID-19 vaccine in immunosuppressed adults and those with autoimmune diseases.

November 23, 2021

Robert Terkeltaub, MD, explains the results from a phase 2, dose-finding study to determine the safety and efficacy of tigulixostat in patients with gout.

November 22, 2021

Robert F Spiera, MD, explains background mycophenolate treatment and its associated improved outcomes in patients with systemic sclerosis receiving lenabasum.

November 15, 2021

Jeffrey Curtis, MD, MS, MPH, discusses malignancies in older patients with rheumatoid arthritis and cardiovascular risks being treated with either tofacitinib or tumor necrosis factor (TNF) inhibitors.